Chemical compound
Pharmaceutical compound
Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor)receptor agonist and is the first medication that targetsPPAR-alpha,PPAR-beta, andPPAR-gamma simultaneously.[1][2][3] As of 2023, it is in a phase III trial fornonalcoholic steatohepatitis; its advantage over other drugs that are in phase III trials for the same condition is that it has shown improvements in bothsteatohepatitis andfibrosis.[4]
- ^Derrett-Smith, Emma; Clark, Kristina E. N.; Shiwen, Xu; Abraham, David J.; Hoyles, Rachel K.; Lacombe, Olivier; Broqua, Pierre; Junien, Jean Louis; Konstantinova, Irena; Ong, Voon H.; Denton, Christopher P. (6 September 2021)."The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis".Arthritis Research & Therapy.23 (1): 234.doi:10.1186/s13075-021-02592-x.ISSN 1478-6362.PMC 8419933.PMID 34488870.
- ^Boyer-Diaz, Zoe; Aristu-Zabalza, Peio; Andrés-Rozas, María; Robert, Claude; Ortega-Ribera, Martí; Fernández-Iglesias, Anabel; Broqua, Pierre; Junien, Jean-Louis; Wettstein, Guillaume; Bosch, Jaime; Gracia-Sancho, Jordi (May 2021)."Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease".Journal of Hepatology.74 (5):1188–1199.doi:10.1016/j.jhep.2020.11.045.PMID 33278455.
- ^Francque, Sven M.; Bedossa, Pierre; Ratziu, Vlad; Anstee, Quentin M.; Bugianesi, Elisabetta; Sanyal, Arun J.; Loomba, Rohit; Harrison, Stephen A.; Balabanska, Rozalina; Mateva, Lyudmila; Lanthier, Nicolas; Alkhouri, Naim; Moreno, Christophe; Schattenberg, Jörn M.; Stefanova-Petrova, Diana; Vonghia, Luisa; Rouzier, Régine; Guillaume, Maeva; Hodge, Alexander; Romero-Gómez, Manuel; Huot-Marchand, Philippe; Baudin, Martine; Richard, Marie-Paule; Abitbol, Jean-Louis; Broqua, Pierre; Junien, Jean-Louis; Abdelmalek, Manal F. (21 October 2021)."A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH".New England Journal of Medicine.385 (17):1547–1558.doi:10.1056/NEJMoa2036205.hdl:10067/1822390151162165141.ISSN 0028-4793.PMID 34670042.
- ^Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023)."Clinical Trial Landscape in NASH".Clinical Gastroenterology and Hepatology.21 (8):2001–2014.doi:10.1016/j.cgh.2023.03.041.PMID 37059159.S2CID 258115543.
